Int J Gynecol Pathol 2021 Mar 29. Epub 2021 Mar 29.
Departments of Pathology and Laboratory Medicine (A.C., E.N.R., T.S., C.F., P.S.W., S.M.M.G.) Obstetrics and Gynecology (A.A.-N.) Carbone Cancer Center (A.A.-N., P.S.W., S.M.M.G.) School of Medicine and Public Health (B.S., N.V.), University of Wisconsin-Madison Department of Pathology, Yale University School of Medicine, New Haven, Connecticut (P.H., N.B.).
There is increasing evidence that many endometrial cancers (EC) diagnosed as clear cell carcinoma (CCC) have substantial overlap with both serous carcinoma (SC) and endometrioid carcinoma (EmC), not only in terms of morphology and immunophenotype but also by molecular characterization. Now with use of HER2-based therapy in SC, a CCC diagnosis in serous-like tumors has the potential to exclude patients from receiving beneficial therapy. To assess HER2 in CCC in relation to other characteristics, a tissue microarray of archived CCC, EmC, and SC was stained for HER2 alongside a battery of immunostains used in EC. Read More